# CYP1A2

## Overview
CYP1A2 is a gene that encodes the enzyme cytochrome P450 family 1 subfamily A member 2, a crucial component of the cytochrome P450 superfamily. This enzyme is primarily expressed in the liver and is involved in the oxidative metabolism of a wide range of endogenous and exogenous compounds, including drugs, environmental chemicals, and procarcinogens. As a monooxygenase, CYP1A2 plays a significant role in the detoxification processes and chemical homeostasis within the body. The enzyme's activity is influenced by its interactions with other proteins, such as NADPH-cytochrome P450 reductase and cytochrome b5, which modulate its function. Genetic polymorphisms in the CYP1A2 gene have been linked to various clinical outcomes, including drug metabolism variability and disease susceptibility, highlighting its importance in pharmacogenomics and personalized medicine (Cornelis2004Genetic; Zhou2009Structure; Connick2017Characterization).

## Structure
The human CYP1A2 protein is a member of the cytochrome P450 superfamily, characterized by a complex molecular structure. The primary structure of CYP1A2 consists of 515 amino acids, with a molecular mass of 58,294 Da (Zhou2009Structure). The secondary structure includes 12 α-helices (A-L) and 4 β-sheets (1-4), forming a compact and planar active site cavity (Zhou2009Insights; Zhou2009Structure). This active site is narrow and planar, suitable for binding planar compounds such as caffeine and theophylline (Zhou2009Structure).

The tertiary structure of CYP1A2 features a heme-binding domain at its core, with the proximal surface providing binding sites for NADPH-cytochrome P450 reductase and cytochrome b5 (Zhou2009Structure). The active site is lined by residues on helices F and I, forming a planar binding platform, with helix I bending across the heme group to create a flat side of the cavity (Zhou2009Structure). Specific residues, such as F226 on helix F, contribute to substrate binding through π-π stacking interactions (Zhou2009Structure).

CYP1A2 is subject to post-translational modifications, including phosphorylation and glycosylation, which may influence its activity and interactions with other proteins. The quaternary structure involves potential interactions with other proteins, although specific details are not provided in the context.

## Function
CYP1A2 is a crucial enzyme in the cytochrome P450 superfamily, predominantly expressed in the liver, where it plays a significant role in the oxidative metabolism of both endogenous and exogenous compounds. In healthy human cells, CYP1A2 is involved in the metabolism of several important endogenous substrates, including melatonin, bilirubin, uroporphyrinogen, estrone, estradiol, and arachidonic acid. It is particularly active in catalyzing the oxidation of uroporphyrinogen to uroporphyrin and is a major enzyme responsible for the 2-hydroxylation of 17β-estradiol and estrone in extrahepatic tissues, such as the breast (Zhou2009Structure).

CYP1A2 also plays a role in the metabolism of retinoids, converting all-trans-retinol to all-trans-retinal and further oxidizing it to retinoic acid. It generates hydroxyeicosatetraenoic and epoxyeicosatrienoic fatty acids from arachidonic acid, contributing to various physiological processes (Zhou2009Structure). The enzyme's activity in metabolizing these compounds is essential for maintaining chemical homeostasis and detoxification processes within the body. Its function in metabolizing environmental compounds and procarcinogens, such as polycyclic aromatic hydrocarbons, highlights its role in protecting against chemical-induced toxicity (Zhou2009Structure).

## Clinical Significance
Mutations and polymorphisms in the CYP1A2 gene have significant clinical implications. The CYP1A2*7 mutation, characterized by a 3533G>A change at the splice donor site of intron 6, results in a loss of enzyme activity and has been associated with elevated plasma concentrations of clozapine, a drug used in schizophrenia treatment (Zhou2009Insights). The CYP1A2*1F polymorphism is linked to an increased risk of myocardial infarction, independent of smoking status, suggesting a role in coronary heart disease through the formation of DNA adducts by tobacco smoke mutagens (Cornelis2004Genetic).

In prostate cancer, certain CYP1A2 polymorphisms, such as rs2470890, are associated with a decreased risk, while others like rs11072508 are linked to higher Gleason scores and advanced pathological stages (Vilčková2023Polymorphisms). In breast cancer, the CYP1A2 rs762551 SNP is associated with early events in patients treated with aromatase inhibitors, indicating its potential as a predictive marker for treatment response (Simonsson2016CYP1A2).

These findings underscore the importance of considering CYP1A2 polymorphisms in therapeutic drug monitoring and treatment planning across various conditions.

## Interactions
CYP1A2 interacts with several proteins, forming both stable and dynamic complexes that influence its enzymatic activity. It forms heteromeric complexes with CYP2B4, which enhance the apparent affinity of CYP1A2 for NADPH-cytochrome P450 reductase (POR), suggesting a specific protein complex formation. This interaction is significant in modulating the function of P450 enzymes, as the presence of CYP2B4 can enhance CYP1A2-mediated activity in certain conditions (Connick2017Characterization).

CYP1A2 also forms a trimeric complex with CYP2B4 and POR, where POR selectively binds to the CYP1A2 moiety. This complex formation is stable and not disrupted by the presence of untagged POR, indicating a strong interaction between these proteins (Connick2017Characterization). The interactions between CYP1A2 and POR are dynamic, with POR capable of disrupting CYP1A2 homomeric complexes, thereby modulating its activity (Connick2017Characterization).

In addition to interactions with CYP2B4, CYP1A2 can form heteromeric complexes with CYP2E1. These interactions are sensitive to ionic strength, with higher ionic strength disrupting the complex formation, suggesting the involvement of electrostatic interactions (Kelley2006Heteromeric). These protein-protein interactions are crucial for understanding the regulation and function of CYP1A2 in drug metabolism.


## References


[1. (Zhou2009Insights) Shu-Feng Zhou, Li-Ping Yang, Zhi-Wei Zhou, Ya-He Liu, and Eli Chan. Insights into the substrate specificity, inhibitors, regulation, and polymorphisms and the clinical impact of human cytochrome p450 1a2. The AAPS Journal, 11(3):481–494, July 2009. URL: http://dx.doi.org/10.1208/s12248-009-9127-y, doi:10.1208/s12248-009-9127-y. This article has 169 citations.](https://doi.org/10.1208/s12248-009-9127-y)

[2. (Connick2017Characterization) J. Patrick Connick, James R. Reed, and Wayne L. Backes. Characterization of interactions among cyp1a2, cyp2b4, and nadph-cytochrome p450 reductase: identification of specific protein complexes. Drug Metabolism and Disposition, 46(3):197–203, December 2017. URL: http://dx.doi.org/10.1124/dmd.117.078642, doi:10.1124/dmd.117.078642. This article has 12 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1124/dmd.117.078642)

[3. (Cornelis2004Genetic) M C Cornelis. Genetic polymorphism of cyp1a2 increases the risk of myocardial infarction. Journal of Medical Genetics, 41(10):758–762, October 2004. URL: http://dx.doi.org/10.1136/jmg.2004.022012, doi:10.1136/jmg.2004.022012. This article has 64 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1136/jmg.2004.022012)

[4. (Kelley2006Heteromeric) Rusty W. Kelley, Dongmei Cheng, and Wayne L. Backes. Heteromeric complex formation between cyp2e1 and cyp1a2: evidence for the involvement of electrostatic interactions. Biochemistry, 45(51):15807–15816, December 2006. URL: http://dx.doi.org/10.1021/bi061803n, doi:10.1021/bi061803n. This article has 37 citations and is from a peer-reviewed journal.](https://doi.org/10.1021/bi061803n)

[5. (Simonsson2016CYP1A2) Maria Simonsson, Srinivas Veerla, Andrea Markkula, Carsten Rose, Christian Ingvar, and Helena Jernström. Cyp1a2 – a novel genetic marker for early aromatase inhibitor response in the treatment of breast cancer patients. BMC Cancer, March 2016. URL: http://dx.doi.org/10.1186/s12885-016-2284-3, doi:10.1186/s12885-016-2284-3. This article has 12 citations and is from a peer-reviewed journal.](https://doi.org/10.1186/s12885-016-2284-3)

[6. (Zhou2009Structure) Shu-Feng Zhou, Bo Wang, Li-Ping Yang, and Jun-Ping Liu. Structure, function, regulation and polymorphism and the clinical significance of human cytochrome p450 1a2. Drug Metabolism Reviews, 42(2):268–354, December 2009. URL: http://dx.doi.org/10.3109/03602530903286476, doi:10.3109/03602530903286476. This article has 297 citations and is from a peer-reviewed journal.](https://doi.org/10.3109/03602530903286476)

[7. (Vilčková2023Polymorphisms) Marta Vilčková, Mária Škereňová, Dušan Dobrota, Peter Kaplán, Jana Jurečeková, Ján Kliment, Márk Híveš, Róbert Dušenka, Daniel Evin, Martina Brožová, and Monika Sivoňová. Polymorphisms in the gene encoding cyp1a2 influence prostate cancer risk and progression. Oncology Letters, January 2023. URL: http://dx.doi.org/10.3892/ol.2023.13671, doi:10.3892/ol.2023.13671. This article has 2 citations and is from a peer-reviewed journal.](https://doi.org/10.3892/ol.2023.13671)